摘要
目的探讨帕罗西汀联合降糖药物治疗2型糖尿病的疗效及安全性。方法收集2型糖尿病血糖控制差者，采用Zung的焦虑抑郁自评量表进行问卷调查，SDS，SAS标准分〉50的患者178例入组，随机分治疗组和观察组。治疗组同时口服帕罗西汀，观察组口服安慰剂。结果24周后两组患者血糖、糖化血红蛋白（HbA1c）均较治疗前明显下降。观察组HbA1c下降29．1％，显著高于对照组的21．6％（P〈0．05）。空腹血糖≤7mmol／L界定为空腹血糖达标，观察组89％达标，对照组16．6％，差异有显著性（P〈0．01）。结论2型糖尿病血糖控制欠佳患者，帕罗西汀联合降糖治疗，血糖控制更为理想。
Objective To explore the efficacy and safety of paroxetine combined with hypoglycemic medications in the treatment of type 2 diabetes. Methods Type 2 diabetic patients with poorly controlled blood glucose level were surveyed by questionnaires with the Zung Self-rating Depression, scale. 178 patients with SDS and SAS standard scores of 〉 50 were included in this study and were randomly divided into two groups Study group and control group. In addition to hypoglycemic agents, the study group received oral paroxetine while the control group was administered placebo. Results Levels of blood glucose and glycated hemoglobin （ HbA1c ） decreased significantly 24 weeks after treatment. HbA 1 c level decreased 29.1% in the study group and 21.6% in the control group （ P〈 0.05 ）. Fasting blood glucose level of ≤ 7 mmol/L was defined as standard contol of fasting blood glucos： 89% of the patients in study group reached this standard and 16.6% in the control group, with a significant statistical difference （ P〈 0.01 ）. Conclusions For type 2 diabetic patients with poorly controlled blood glucose level, paroxetine combined with hypoglycemic therapy is more efficacious in the control of glucose level.
出处
《国际医药卫生导报》
2012年第9期1253-1255,共3页
International Medicine and Health Guidance News
关键词
帕罗西汀
糖尿病
焦虑抑郁
Paroxetine
Diabetes
Anxiety and depression
